We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+12.22%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$360M
AUM Growth
+$92.4M
Cap. Flow
+$88.5M
Cap. Flow %
24.56%
Top 10 Hldgs %
19.65%
Holding
155
New
60
Increased
18
Reduced
21
Closed
31

Top Buys

Rank Stock Value
1
BIOR
Biora Therapeutics, Inc. Common Stock
BIOR
+$9.64M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$6.47M
3
ALDX icon
Aldeyra Therapeutics
ALDX
+$6.31M
4
CDNA icon
CareDx
CDNA
+$6.31M
5
VRCA icon
Verrica Pharmaceuticals
VRCA
+$6.28M

Top Sells

Rank Stock Value
1
IRD
Opus Genetics
IRD
+$15.5M
2
GNPX icon
Genprex
GNPX
+$6.81M
3
ANAB icon
AnaptysBio
ANAB
+$5.62M
4
COGT icon
Cogent Biosciences
COGT
+$4.86M
5
CLDX icon
Celldex Therapeutics
CLDX
+$4.47M

Sector Composition

Rank Sector Weight
1 Healthcare 82.98%
2 Financials 2.24%
3 Consumer Staples 0.95%
4 Industrials 0.89%
5 Technology 0.63%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCRX icon
126
BioCryst Pharmaceuticals
BCRX
$2.4B
– –
-250,000
Closed -$1.86M
CLRB icon
127
Cellectar Biosciences
CLRB
$20.5M
– –
-2,840
Closed -$1.77M
CNSP icon
128
CNS Pharmaceuticals
CNSP
$7.86M
– –
-1
Closed -$951K
COGT icon
129
Cogent Biosciences
COGT
$7.24B
– –
-432,563
Closed -$4.86M
CRDF icon
130
Cardiff Oncology
CRDF
$77.2M
– –
-185,552
Closed -$3.34M
DXCM icon
131
DexCom
DXCM
$32B
– –
-22,000
Closed -$2.03M
ICUI icon
132
ICU Medical
ICUI
$4.61B
– –
-9,321
Closed -$2M
IMUX icon
133
Immunic
IMUX
$195M
– –
-24,416
Closed -$3.73M
KPTI icon
134
Karyopharm Therapeutics
KPTI
$48M
– –
-8,930
Closed -$2.07M
LYRA
135
DELISTED
LYRA THERAPEUTICS INC
LYRA
– –
-104
Closed -$59K
NNDM
136
Nano Dimension
NNDM
$343M
– –
-304,600
Closed -$2.77M
OPTN
137
DELISTED
OptiNose
OPTN
– –
-30,573
Closed -$1.9M
RIGL icon
138
Rigel Pharmaceuticals
RIGL
$750M
– –
-57,103
Closed -$2M
SCYX icon
139
SCYNEXIS
SCYX
$52M
– –
-50,000
Closed -$3.06M
TLSA icon
140
Tiziana Life Sciences
TLSA
$127M
– –
-1,077,883
Closed -$2.18M
VERO
141
DELISTED
Venus Concept
VERO
– –
-568
Closed -$162K
ATYR
142
aTyr Pharma
ATYR
$50.1M
– –
-332,258
Closed -$1.29M
VINC
143
DELISTED
Vincerx Pharma, Inc. Common Stock
VINC
– –
-7,508
Closed -$3.14M
KBNT
144
DELISTED
Kubient, Inc. Common Stock
KBNT
– –
-42,269
Closed -$236K
NMTR
145
DELISTED
9 Meters Biopharma
NMTR
– –
-63,250
Closed -$1.09M
OIG
146
DELISTED
Orbital Infrastructure Group, Inc. Common Stock
OIG
– –
-33,850
Closed -$2.96M
OTIC
147
DELISTED
Otonomy, Inc.
OTIC
– –
-299,890
Closed -$1.94M
QTNT
148
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-623
Closed -$130K
EPZM
149
DELISTED
Epizyme, Inc
EPZM
– –
-130,000
Closed -$1.41M
CEREW
150
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
– –
-64,666
Closed -$365K
3 4 5
6
7

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
ICP
Indus Capital Partners New York $39.7M AUM 53.95% 1-Year Est. Return

Altium Capital Management's Q1 2021 Portfolio in Review

As of Q1 2021, Altium Capital Management held 155 positions worth $360M, up 34% from $268M the previous quarter. Its ten largest holdings account for 20% of the portfolio.

Altium Capital Management deployed $88.5M of net new capital in Q1 2021, opening 60 new positions and adding to 18 existing holdings. Its largest new stake was Biora Therapeutics, Inc. Common Stock: 6,993 shares worth $8.32M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 85% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was Opus Genetics, an estimated $15.5M trimmed.

  • Altium Capital Management's largest Q1 2021 buy was Biora Therapeutics, Inc. Common Stock: 6,993 shares worth $8.32M.
  • Altium Capital Management added most to Verrica Pharmaceuticals in Q1 2021, an estimated $6.28M increase.
  • Altium Capital Management's biggest Q1 2021 reduction was Opus Genetics, cutting an estimated $15.5M.
  • Altium Capital Management fully exited AnaptysBio in Q1 2021, selling an estimated $5.62M.
  • Altium Capital Management's ten largest holdings make up 20% of its $360M portfolio in Q1 2021.
  • Altium Capital Management opened 60 new positions and closed 31 in Q1 2021.
  • Altium Capital Management's portfolio value rose 34% quarter-over-quarter to $360M.

Based on Altium Capital Management's 13F filing for Q1 2021, filed 6 May 2021.